Metastatic Urothelial Carcinoma Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment
Explore our latest breakthroughs in Metastatic Urothelial Carcinoma Research. Learn more about our innovative pipeline today! @ Metastatic Urothelial Carcinoma Pipeline Outlook
Key Takeaways from the Metastatic Urothelial Carcinoma Pipeline Report
In July 2025, Inovio Pharmaceuticals announced a Phase I/IIA, open-label, multi-center trial to evaluate the safety, immunogenicity and preliminary clinical efficacy of INO-5401 + INO-9012 delivered by intramuscular (IM) injection followed by electroporation (EP), in combination with atezolizumab in participants with locally advanced unresectable or metastatic/recurrent Urothelial Carcinoma (UCa).
In July 2025, Merck Sharp & Dohme LLC conducted a substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1/ligand 1 (PD-1/L1) inhibitors. The protocol infrastructure will enable the rolling assignment of investigational treatments.
In July 2025, Seagen organized a study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease.
DelveInsight's Metastatic Urothelial Carcinoma pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Metastatic Urothelial Carcinoma treatment.
The leading Metastatic Urothelial Carcinoma Companies such as PharmaMar, Ectin Research AG, Exelixis, Eli Lilly and Company, Merck Sharp & Dohme LLC, Astellas Pharma Inc, Seagen Inc., Shanghai Miracogen Inc., Advaxis, Inc. and others.
Promising Metastatic Urothelial Carcinoma Pipeline Therapies such as BT8009, Olaparib, Enfortumab vedotin, Nivolumab, Gemcitabine, Carboplatin, Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Ipilimumab, Tremelimumab and others.
Stay informed about the cutting-edge advancements in Metastatic Urothelial Carcinoma treatments. Download for updates and be a part of the revolution in oncology Care @ Metastatic Urothelial Carcinoma Clinical Trials Assessment
Metastatic Urothelial Carcinoma Emerging Drugs Profile
MFA 370: Ectin Research AG
Urothelial bladder cancer is one of the world's most aggressive cancers, current treatments can be tough to tolerate. MFA-370 is planned to be a simple oral tablet developed to eliminate tumors safely, with few if any side effects. MFA-370 is a combination of a medication from that substance family, together with one other standard, well-established drug. Both are tried, tested and trusted treatments that have already undergone large-scale clinical trials. It already demonstrated efficacy in preclinical results and 'patient zero' case. In addition to MFA-370 showing positive preclinical results in metastatic urothelial bladder cancer, it has also eliminated prostate, breast and colorectal cancer cells in preclinical tests too. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Metastatic Urothelial Carcinoma.
XL 092: Exelixis
XL092 is a next-generation oral TKI that builds on our extensive experience with cabozantinib. XL092 also targets VEGF receptors, MET, TAM kinases and other kinases implicated in cancer's growth and spread. In preclinical tumor models, XL092 showed excellent activity as a single agent and in combination with ICIs. XL092 also has an optimized pharmacokinetic profile aimed at facilitating adverse event management in the clinic. XL092 is the first new Exelixis-discovered compound to come out of the company's reinitiated drug discovery activities, which entered phase 1 clinical development in 2019. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic Urothelial Carcinoma.
Lurbinectedin: PharmaMar
Lurbinectedin, also known as PM01183, or commercially where approved as Zepzelca® is an analogue of a similar natural compound ET-736 with characteristics that make it similar but different to its parent compounds. Lurbinectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Metastatic Urothelial Carcinoma.
The Metastatic Urothelial Carcinoma Pipeline Report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Urothelial Carcinoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Urothelial Carcinoma Treatment.
Metastatic Urothelial Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Metastatic Urothelial Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Urothelial Carcinoma market.
Learn more about Metastatic Urothelial Carcinoma Drugs opportunities in our groundbreaking Metastatic Urothelial Carcinoma research and development projects @ Metastatic Urothelial Carcinoma Unmet Needs
Metastatic Urothelial Carcinoma Companies
PharmaMar, Ectin Research AG, Exelixis, Eli Lilly and Company, Merck Sharp & Dohme LLC, Astellas Pharma Inc, Seagen Inc., Shanghai Miracogen Inc., Advaxis, Inc. and others.
Metastatic Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Metastatic Urothelial Carcinoma Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Discover the latest advancements in Metastatic Urothelial Carcinoma treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Metastatic Urothelial Carcinoma Market Drivers and Barriers, and Future Perspectives
Scope of the Metastatic Urothelial Carcinoma Pipeline Report
Coverage- Global
Metastatic Urothelial Carcinoma Companies- PharmaMar, Ectin Research AG, Exelixis, Eli Lilly and Company, Merck Sharp & Dohme LLC, Astellas Pharma Inc, Seagen Inc., Shanghai Miracogen Inc., Advaxis, Inc. and others.
Metastatic Urothelial Carcinoma Pipeline Therapies- BT8009, Olaparib, Enfortumab vedotin, Nivolumab, Gemcitabine, Carboplatin, Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Ipilimumab, Tremelimumab and others.
Metastatic Urothelial Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Metastatic Urothelial Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Urothelial Carcinoma Pipeline on our website @ Metastatic Urothelial Carcinoma Emerging Drugs and Companies
Table of Contents
Introduction
Executive Summary
Metastatic Urothelial Carcinoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Metastatic Urothelial Carcinoma– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Drug name : Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Lurbinectedin: PharmaMar
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
XL 092: Exelixis
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name : Company name
Inactive Products
Metastatic Urothelial Carcinoma Key Companies
Metastatic Urothelial Carcinoma Key Products
Metastatic Urothelial Carcinoma- Unmet Needs
Metastatic Urothelial Carcinoma- Market Drivers and Barriers
Metastatic Urothelial Carcinoma- Future Perspectives and Conclusion
Metastatic Urothelial Carcinoma Analyst Views
Metastatic Urothelial Carcinoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
14 minutes ago
- Globe and Mail
Wolverine Worldwide Announces Second Quarter Fiscal 2025 Conference Call for August 6, 2025
Wolverine World Wide, Inc. (NYSE: WWW) today announced that it expects to report its second quarter fiscal 2025 financial results on Wednesday, August 6, 2025, at approximately 6:30 a.m. ET. Following the press release, the Company will host a conference call at 8:30 a.m. ET to review results and discuss current business trends. Investors and analysts interested in joining the call are invited to dial 1-800-715-9871 (international callers, please dial 1-646-307-1963) approximately five minutes prior to the start of the call. The conference call will be broadcast live and accessible under 'Webcasts & Presentations' in the Investor Relations section of A recorded replay of the call will be available shortly after the conclusion of the call and remain available until August 13, 2025. To access the telephone replay, dial 1-800-770-2030 (international callers, please dial 1-609-800-9909). The access code for the replay is 9927992. ABOUT WOLVERINE WORLDWIDE Founded in 1883, Wolverine World Wide, Inc. (NYSE:WWW) is one of the world's leading designers, marketers, and licensors of branded casual footwear and apparel, performance outdoor and athletic footwear and apparel, kids' footwear, industrial work boots and apparel, and uniform footwear. The Company's portfolio includes Merrell®, Saucony®, Sweaty Betty®, Hush Puppies®, Wolverine®, Chaco®, Bates®, HYTEST®, and Stride Rite®. Wolverine Worldwide is also the global footwear licensee of the popular brands Cat® and Harley-Davidson®. Based in Rockford, Michigan, for more than 140 years, the Company's products are carried by leading retailers in the U.S. and globally in approximately 170 countries and territories. Wolverine Worldwide is a Great Place to Work® Certified™ company. For additional information, please visit our website,
Globe and Mail
14 minutes ago
- Globe and Mail
Spectrum Brands Holdings to Report Fiscal 2025 Third Quarter Financial Results and Hold Conference Call and Webcast on August 7, 2025
Spectrum Brands Holdings, Inc. (NYSE: SPB; 'Spectrum Brands'), a leading global branded consumer products and home essentials company focused on driving innovation and providing exceptional customer service, announced today it will release its fiscal 2025 third quarter financial results for the period ended June 29, 2025 before the markets open on Thursday, August 7, 2025. Spectrum Brands will conduct a live conference call and live webcast on August 7, 2025 at 9:00 a.m. Eastern Time (8:00 a.m. Central Time), which will be hosted by David Maura, Executive Chairman and Chief Executive Officer, and Jeremy Smeltser, Executive Vice President and Chief Financial Officer. The live webcast and related presentation slides will be available by visiting the Event Calendar page in the Investor Relations section of Spectrum Brands' website at Participants may register for the call here. Instructions will be provided to ensure the necessary audio applications are downloaded and installed. Users can obtain these at no charge. Following the call, a replay of the live broadcast also will be accessible through the Event Calendar page in the Investor Relations section of Spectrum Brands' website. About Spectrum Brands Holdings, Inc. Spectrum Brands is a home-essentials company with a mission to make living better at home. We focus on delivering innovative products and solutions to consumers for use in and around the home through our trusted brands. We are a leading supplier of specialty pet supplies, lawn and garden and home pest control products, personal insect repellents, shaving and grooming products, personal care products, and small household appliances. Helping to meet the needs of consumers worldwide, we offer a broad portfolio of market-leading, well-known and widely trusted brands including Tetra®, DreamBone®, SmartBones®, Nature's Miracle®, 8-in-1®, FURminator®, Healthy-Hide®, Good Boy®, Meowee!®, OmegaOne®, Spectracide®, Cutter®, Repel®, Hot Shot®, Rejuvenate®, Black Flag®, Liquid Fence®, Remington®, George Foreman®, Russell Hobbs®, BLACK + DECKER®, PowerXL®, Emeril Lagasse®, and Copper Chef®. For more information, please visit Spectrum Brands – A Home Essentials Company™.
Globe and Mail
14 minutes ago
- Globe and Mail
NANO Nuclear Completes Assembly of Its Proprietary Annular Linear Induction Pump Technology Prototype for Critical Test Loop Validation In SBIR Phase III Program
Milestone demonstrates NANO Nuclear's ability to bring advanced nuclear technology from initial design to construction and demonstration New York, New York--(Newsfile Corp. - July 23, 2025) - NANO Nuclear Energy Inc. (NASDAQ: NNE) ("NANO Nuclear" or "the Company"), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that its proprietary, patent pending Annular Linear Induction Pump (ALIP) technology for nuclear reactors has been assembled onto a test loop and integrated to a controllable test setup for variable design validation at NANO Nuclear's Demonstration Facility in Westchester County, New York. As NANO Nuclear continues progress with its microreactor programs, including its lead KRONOS MMR TM Energy System project, the ALIP assembly milestone demonstrates NANO Nuclear's leadership in advanced nuclear energy technology and its ability to move technology from initial design to construction and demonstration. NANO Nuclear hopes to be able to start commercial sales activities for ALIP by the end of this year or next year. This milestone also underscores the utility of NANO Nuclear's Westchester Demonstration Facility, which became operational earlier this year. "This initial milestone with ALIP shows in a small but very promising way what we can do as a company in the real world," said James Walker, Chief Executive Officer of NANO Nuclear. "ALIP is an enabling technology that supports the development of next-generation reactors utilizing molten salts or liquid metals, and advancing ALIP through the SBIR Phase III process has allowed us to mature the system extensively, refining its design, validating key performance metrics, and preparing it for integration into demonstration-scale platforms at our custom-built Westchester facility. This progress not only enhances the technology's readiness for deployment but also opens a clear pathway toward revenue generating activities for NANO Nuclear as we progress work on our broader portfolio of advanced nuclear technologies." The ALIP technology is a thermal management and distribution system within NANO Nuclear's suite of advanced nuclear energy technologies. It operates using electromagnetic, in place of mechanical, pumps, and could serve as a critical component in the development of advanced molten-salt and liquid-metal nuclear reactors. As previously announced, earlier this year, NANO Nuclear collaborated with aRobotics Company, a leading innovator in robotics fabrication, inspection, engineering and testing, to support NANO Nuclear's ongoing SBIR Phase III program for ALIP, which was previously funded by the U.S Department of Energy. Data from the test and validation work being done will be leveraged to support the SBIR Phase III program. Figure 1 - NANO Nuclear Energy 's ALIP Technology (center) integrated on the Test Loop inside Custom-Engineered Thermal Chamber at the Demonstration Facility in Westchester County, New York. To view an enhanced version of this graphic, please visit: "Developing the first iteration of NANO Nuclear's ALIP and its adjacent test instrumentation enables us to collect crucial data and advance this project towards its ultimate goal of commercialization," said Jay Yu, Founder and Chairman of NANO Nuclear. "With the support of aRobotics Company, we plan to steadily develop and test additional generations of ALIP as we improve the technology's readiness for the market." To view an enhanced version of this graphic, please visit: "We believe ALIP will have a number of applications upon development including in the space and defense sectors," said Akaash Kancharla, CEO of aRobotics Company. "The procedural knowledge and material science advanced by this work will have implications far beyond this useful product." By utilizing a time-varying magnetic field, ALIPs enable the movement of conductive fluids without mechanical components, reducing wear and maintenance requirements while increasing efficiency. Current efforts at the NANO Nuclear Demonstration Facility are geared towards the development of the first operational ALIP prototype and a custom designed test loop for research data collection, alongside a magnetic field mapping system, for the collection of manufacturing and performance data. Future work will include testing and characterizing pump performance with different working fluids, simulating component failure scenarios, and material testing. To view an enhanced version of this graphic, please visit: About NANO Nuclear Energy Inc. NANO Nuclear Energy Inc. (NASDAQ: NNE) is an advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel fabrication, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services. NANO Nuclear believes it is the first portable nuclear microreactor company to be listed publicly in the U.S. Led by a world-class nuclear engineering team, NANO Nuclear's reactor products in development include patented KRONOS MMR ™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign (U. of I.), " ZEUS", a solid core battery reactor, and " ODIN", a low-pressure coolant reactor, and the space focused, portable LOKI MMR ™, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors. Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, is led by former executives from the largest transportation company in the world aiming to build a North American transportation company that will provide commercial quantities of HALEU fuel to small modular reactors, microreactor companies, national laboratories, military, and DOE programs. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy. Assuming development and commercialization, AFT is expected to form part of the only vertically integrated nuclear fuel business of its kind in North America. HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear's own microreactors as well as the broader advanced nuclear reactor industry. NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear's developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR ™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS' initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon's surface. For more corporate information, please visit: For further NANO Nuclear information, please contact: Email: IR@ Business Tel: (212) 634-9206 PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE: NANO Nuclear Energy LINKEDIN NANO Nuclear Energy YOUTUBE NANO Nuclear Energy X PLATFORM Cautionary Note Regarding Forward-Looking Statements This news release and statements of NANO Nuclear's management and collaborators in connection with this news release contain or may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as "expects", "anticipates", "intends", "plans", "believes", "potential", "will", "should", "could", "would," "seek," "hope, "may" and other words of similar meaning. In this press release, forward-looking statements include those related to NANO Nuclear's development and commercialization plans for the ALIP technology. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to the following: (i) risks related to our U.S. Department of Energy ("DOE") or related state or non-U.S. nuclear licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complimentary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) our ability to obtain contracts and funding to be able to continue operations, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the DOE and the U.S. Nuclear Regulatory Commission, including those associated with the recently enacted ADVANCE Act and the May 23, 2025 Executive Orders seeking to streamline nuclear regulation, and (vi) similar risks and uncertainties associated with the operating an early stage business a highly regulated and rapidly evolving industry. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at and at Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
